A Budget Impact And Cost Per Additional Responder Analysis For Baricitinib For The Treatment Of Moderate-To-Severe Rheumatoid Arthritis In Patients With An Inadequate Response To Tumor Necrosis Factor Inhibitors In The Usa (August, 10.1007/S40273-019-00829-X, 2019)